Chetasi Talati, MD, discusses early results from a multicenter chart review examining treatment patterns and outcomes of patients with newly diagnosed AML who received venetoclax/HMA combinations in the real-world setting and the next phase of the ongoing research initiative.
Chetasi Talati, MD
Chetasi Talati, MD
The recently-approved hypomethylating treatment, Inoqvi, is a daily oral version of two IV or subcutaneous medications. Listen to Dr. Amer Zeidan of Yale Cancer Center explain which MDS patients could qualify, and what it means for their treatment at the link.
Since treatment in July 2019, I have still been transfusion-dependent, receiving both blood and platelets. I get so short of breath when my blood is low. I really hate this disease. Because I’m still transfusion-dependent, I go back and forth for labs, doctor’s appointments, and transfusions.
Matt Kalaycio, MD, FACP, is the former Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic Taussig Cancer Institute. Dr. Kalaycio is also a Professor in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Board-certified in hematology, Dr. Kalaycio's clinical interests are in leukemia and hematopoietic cell transplantation.
Dr. Leslie Ellis is a hematologist-oncologist at Wake Forest Baptist Health in Winston-Salem North Carolina. Dr.